Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Hyperthyroidism II: Pathophysiology01:27

Hyperthyroidism II: Pathophysiology

Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Advanced metal-phenolic networks for tissue regeneration: opportunities and challenges.

Journal of nanobiotechnology·2026
Same author

How stratospheric intrusion modulates the optimal mitigation pathway for ozone under sharp emission reductions.

Ecotoxicology and environmental safety·2026
Same author

Sanguinarine as a multi-target therapeutic candidate for laryngeal cancer: insights from network pharmacology, molecular dynamics and in vitro validation.

BMC cancer·2026
Same author

Spatial distribution of the proteome in the human body and in cancers.

Nature·2026
Same author

Exploring the material basis and potential mechanism of spleen-strengthening and damp-resolving prescriptions in the treatment of diabetes mellitus complicated with obesity based on data mining, UPLC-Q-TOF-MS/MS and network pharmacology.

Naunyn-Schmiedeberg's archives of pharmacology·2026
Same author

Timing of a single dexmedetomidine bolus to attenuate remifentanil-induced hyperalgesia after thyroidectomy: a randomized controlled trial.

BMC anesthesiology·2026

Related Experiment Video

Updated: Jul 9, 2026

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
08:09

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease

Published on: January 7, 2014

Hyperthyroidism Is Genetically Associated With Reduced Risk of Parkinson's Disease: A Mendelian Randomization

Meng Luo1, Shiren Huang2, Wei Wang3

  • 1Department of Neurology, Bazhong Traditional Chinese Medicine Hospital (Bazhou District People's Hospital of Bazhong City), Bazhong, Sichuan Province, China.

The European Journal of Neuroscience
|July 8, 2026
PubMed
Summary

Hyperthyroid disease states like Graves' disease may offer protection against Parkinson's disease (PD) risk. This genetic study suggests a potential link between thyroid function and neurodegeneration, warranting further investigation into the thyroid-brain axis.

Keywords:
Graves' diseaseMendelian randomizationParkinsons' diseasethyroid dysfunctionthyrotoxicosis

Related Experiment Videos

Last Updated: Jul 9, 2026

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
08:09

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease

Published on: January 7, 2014

Area of Science:

  • Neuroscience
  • Endocrinology
  • Genetics

Background:

  • Parkinson's disease (PD) etiology involves complex genetic, immune, metabolic, and environmental factors.
  • Endocrine dysfunction, particularly thyroid hormone signaling, is implicated in neurodegeneration, but previous studies yielded inconsistent results.
  • Prior Mendelian randomization (MR) studies focused on continuous thyroid biomarkers, not clinically defined hyperthyroid states.

Purpose of the Study:

  • To investigate the bidirectional relationship between hyperthyroid disease states and Parkinson's disease risk using a two-sample Mendelian randomization (MR) approach.
  • To clarify the role of thyroid hormone signaling and autoimmune-mediated immune modulation in PD pathogenesis.
  • To explore potential protective effects of hyperthyroidism on PD risk, independent of lifestyle confounders.

Main Methods:

  • Conducted a two-sample bidirectional and multivariable MR (MVMR) analysis using large-scale genome-wide association study (GWAS) summary statistics.
  • Utilized single-nucleotide polymorphisms (SNPs) for Graves' disease and thyrotoxicosis with diffuse goitre as instrumental variables.
  • Employed inverse-variance weighted (IVW) method as primary analysis, with MR-Egger, weighted median, and MVMR adjusted for smoking, alcohol, and BMI for robustness.

Main Results:

  • Genetically proxied Graves' disease (OR=0.942, p=0.008) and thyrotoxicosis with diffuse goitre (OR=0.929, p=0.009) were associated with a reduced risk of PD.
  • Reverse analyses showed no significant effect of genetic liability to PD on thyroid traits.
  • Sensitivity analyses confirmed the stability of inverse associations and found no evidence of heterogeneity or horizontal pleiotropy.

Conclusions:

  • Findings provide genetic evidence supporting a protective relationship between hyperthyroid disease states and PD risk.
  • The thyroid-brain axis, involving thyroid hormone signaling and immune modulation, is a plausible contributor to PD risk.
  • Hyperthyroid disease states may represent a potentially modifiable factor in PD risk, meriting further mechanistic and translational research.